Shares of biopharmaceutical company Praxis Precision Medicines Inc. are soaring, boosted by the successful trial of a new ...

Shares of biopharmaceutical company Praxis Precision Medicines Inc. are soaring, boosted by the successful trial of a new drug to treat movement disorders. The drug, ulixacaltamide, targets essential ...

Ulixacaltamide is a highly selective small molecule T-type calcium channel inhibitor designed to block neuronal bursting in the cerebello-thalamo-cortical circuit linked to tremor activity.

Shares of Praxis Precision Medicines more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive ...

Praxis Precision Medicines’ commitment to forging ahead with ulixacaltamide in essential tremor (ET) has paid off. | The ...

Turning to Wall Street, the analysts’ consensus rating for Praxis Precision Medicines is Strong Buy, based on 10 Buy and a ...

Shares of the Boston company, which closed Wednesday at $57.35, were recently up 109% to $119.83. Praxis said the two Phase 3 studies of ulixacaltamide met their primary endpoints in essential tremor, ...

The company plans to submit an application to the U.S. Food and Drug Administration for approval of Ulixacaltamide in ...

Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modified Activities of ...

Essential tremor is a movement disorder marked by involuntary, rhythmic shaking in the hands but sometimes affecting the head, voice and other areas. Its exact cause is still unknown. Recent research ...

Lindsay Wright, 72, from Colchester, was first diagnosed with essential tremor 15 years ago. Essential tremor is a ...

"It's being open about it [your diagnosis]. Everyone thinks you have Parkinson's and actually, this condition is more common ...